JP2022515152A5 - - Google Patents

Info

Publication number
JP2022515152A5
JP2022515152A5 JP2021535665A JP2021535665A JP2022515152A5 JP 2022515152 A5 JP2022515152 A5 JP 2022515152A5 JP 2021535665 A JP2021535665 A JP 2021535665A JP 2021535665 A JP2021535665 A JP 2021535665A JP 2022515152 A5 JP2022515152 A5 JP 2022515152A5
Authority
JP
Japan
Prior art keywords
seq
recombinant protein
protein according
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067563 external-priority patent/WO2020132291A1/en
Publication of JP2022515152A publication Critical patent/JP2022515152A/ja
Publication of JP2022515152A5 publication Critical patent/JP2022515152A5/ja
Priority to JP2024192700A priority Critical patent/JP2025032075A/ja
Pending legal-status Critical Current

Links

JP2021535665A 2018-12-19 2019-12-19 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体 Pending JP2022515152A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024192700A JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782317P 2018-12-19 2018-12-19
US62/782,317 2018-12-19
PCT/US2019/067563 WO2020132291A1 (en) 2018-12-19 2019-12-19 Baff-r bispecific t-cell engager antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024192700A Division JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Publications (2)

Publication Number Publication Date
JP2022515152A JP2022515152A (ja) 2022-02-17
JP2022515152A5 true JP2022515152A5 (enExample) 2022-12-21

Family

ID=71098268

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535665A Pending JP2022515152A (ja) 2018-12-19 2019-12-19 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体
JP2024192700A Pending JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024192700A Pending JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Country Status (8)

Country Link
US (2) US20200199232A1 (enExample)
EP (1) EP3897720A4 (enExample)
JP (2) JP2022515152A (enExample)
KR (1) KR20210104816A (enExample)
CN (2) CN121405815A (enExample)
AU (1) AU2019404282A1 (enExample)
CA (1) CA3123599A1 (enExample)
WO (1) WO2020132291A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4558522A1 (en) * 2022-07-19 2025-05-28 Novartis AG Treatment of aiha with baff or baff receptor inhibitory antibodies
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
AU2024227909A1 (en) * 2023-02-28 2025-08-14 Mayo Foundation For Medical Education And Research Molecules that bind to b-cell activating factor receptor polypeptides
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
CN104780940B (zh) * 2012-11-06 2017-11-07 拜耳制药股份公司 用于双特异性t细胞衔接体(bites)的制剂
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
MX384418B (es) * 2014-07-31 2025-03-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
EP3288981A1 (en) * 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EP3916018A1 (en) * 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
MX2018002043A (es) * 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
IL313507A (en) * 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
EP4628094A3 (en) * 2016-06-06 2025-12-31 City of Hope BAFF-R ANTIBODIES AND THEIR USES
IL308798A (en) * 2016-06-06 2024-01-01 Univ Texas Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
CN113874391B (zh) * 2019-02-20 2025-10-28 希望之城公司 靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途

Similar Documents

Publication Publication Date Title
JP2022515152A5 (enExample)
JP2024020298A5 (enExample)
JP2025111463A5 (enExample)
JP2024167313A5 (enExample)
JP2021184721A5 (enExample)
JP2024096688A5 (enExample)
JP2023123726A5 (enExample)
JP2020180158A5 (enExample)
JP2023058573A5 (enExample)
JP2019535763A5 (enExample)
JP2020531438A5 (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質
JP2023081303A5 (enExample)
JP2021522162A5 (enExample)
CN116396386A (zh) Cd3抗体及其药物用途
JP2018517431A5 (enExample)
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2019502712A5 (enExample)
JP2018193386A5 (enExample)
JP2010526028A5 (enExample)
JP2007532139A5 (enExample)
JP2022533538A5 (enExample)
JP2025032102A5 (enExample)
JP2025038088A5 (enExample)
JP2021520393A5 (enExample)